AI Article Synopsis
- - The study aimed to estimate the prevalence of hepatitis B virus (HBV) among 10-25-year-olds in Mexico using data from the 2012 National Health and Nutrition Survey, analyzing 1,581 serum samples.
- - The results showed a low prevalence of natural infection at 0.23%, with no cases of acute or chronic infection, while vaccination-derived immunity was found to be 44.7%, particularly lower in those aged 20-25 compared to 10-19.
- - The findings suggest that vaccination policies implemented since 1999 have contributed to higher immunity levels in adolescents, highlighting the effectiveness of vaccination in reducing HBV prevalence.
Article Abstract
Objectives: To estimate hepatitis B virus (HBV) seroprevalence from natural infection or vaccination in 10-25-year-olds in Mexico, using the 2012 National Health and Nutrition Survey (ENSANUT).
Methods: Randomly selected serum samples (1,581) from adolescents and young adults, representative of 38,924,584 Mexicans, were analyzed to detect hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc). Weighted HBV seroprevalence in the Mexican population and association with sociodemographic variables were calculated.
Results: Overall weighted seroprevalence from natural infection (positive for anti-HBs and anti-HBc) was 0.23% (95% confidence interval [95% CI] 0.10-0.52). No HBsAg was detected, indicating no acute or chronic infection. Vaccine-derived immunity (positive ≥ 10.0 mIU/ml for anti-HBs and negative to anti-HBc) was 44.7% (95% CI: 40.2-49.4) overall; lower in persons aged 20-25 years (40.83%) than in persons aged 10-19 years (47.7%). Among the population analyzed, 54.2% (95% CI: 49.6-58.8) were seronegative to HBV (negative for all three markers) and no sociodemographic risk factors were identified.
Conclusions: HBV seroprevalence from natural infection was low. Vaccination-induced immunity was higher among Mexican adolescents than young adults, possibly due to vaccination policies since 1999.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422518 | PMC |
| http://dx.doi.org/10.1080/21645515.2018.1533617 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: In 1992, Hepatitis B vaccine was first recommended for routine neonatal immunization in China. This study aimed to estimate the prevalence of hepatitis B virus (HBV) infection in Shandong Province, eastern China (updating our previous study in 2014), and to help guide the efforts of hepatitis B elimination.
Methods: We determined prevalence of HBV infection from the remaining serum samples collected through a population-based survey, which was originally intended for a seroepidemiological survey of anti-SARS-CoV-2 antibodies conducted in 2023.
Prevalence of hepatitis B surface antibody among previously vaccinated healthcare workers in Tashkent, Uzbekistan.
Hum Vaccin Immunother
December 2024
Central Asia Field Epidemiology Training Program, Almaty, Kazakhstan.
Healthcare workers (HCW) have high occupational risk for hepatitis B and Uzbekistan held two HCW vaccination campaigns in 2015 and 2022. Hepatitis B antibody testing (anti-HBs) after Hepatitis B (HepB) vaccination is recommended by the U.S.
View Article and Find Full Text PDFBackground: Hepatitis B virus (HBV) infection is one of the most common health problems worldwide and is associated with high mortality and heavy economic burdens. The aim of this study was to determine the prevalence of hepatitis B surface antigen (HBsAg) and associated risk factors among pregnant women attending antenatal clinics at Adigrat General Hospital in Northern Ethiopia.
Methods: An institutional-based cross-sectional study was conducted from January to March 2024 among 385 pregnant women.
Trends of coinfections among healthy blood donors: COVID-19 pandemic repercussion.
J Family Med Prim Care
October 2024
Department of Immunohematology and Blood Transfusion, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
Background: Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) coinfection has emerged as a leading cause of morbidity throughout the world in the last two decades. The coronavirus disease 2019 (COVID-19) pandemic has escalated the disease burden further by increasing the number of intravenous (IV) drug abusers and unemployment.
Aim: The present study was done to analyse the impact of COVID-19 on seroprevalence as well as trends during pre, post and pandemic years of coinfection and mono-infections in the Malwa region of Punjab.
Seropositivity and coinfection of hepatitis B and hepatitis C viruses in Central India: A hospital-based study.
J Family Med Prim Care
October 2024
State Virology Laboratory, Gandhi Medical College, Bhopal, Madhya Pradesh, India.
Background: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) show similarity in the transmission, distribution, hepatotropism, and leading to chronic asymptomatic infection. Coinfection of HBV and HCV can lead to more severe liver disease and an increased risk for progression to hepatocellular carcinoma (HCC). Most of the people with chronic infection are unaware of their HBV and HCV infections, hence facilitating these to go undiagnosed until these viruses have caused serious liver damage and they act as a potential source of infection for the community at large.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!